Bellerophon Therapeutics Announces $5 Million Registered Direct Offering
WARREN, N.J., March 06, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics...
Year: 2023
Surgalign Provides Update on Corporate Restructuring Initiatives and Confirms its Prior 2022 Revenue Guidance
Company on track to achieve target cash savings of $30 - $35 million in 2023 vs 2022; expects to report...
Anti-Properdin Antibody (NM3086) Demonstrates Efficacy in a Primate Model of Wet-AMD and Dry-AMD
Figure 1 Fluoresceine angiogram data from three animals treated with NM3086 (bottom) and three that received placebo control. The picture...
Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCC
Lorundrostat demonstrated clinically meaningful blood pressure reduction in individuals with uncontrolled hypertension Obesity was predictive of an enhanced response to...
89bio Presents New Analysis of Data from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG regardless...
New Analyses of Sotagliflozin Showing Time to Clinical Benefit Presented at The American College of Cardiology’s 72nd Annual Scientific Session Together With World Heart Federation’s World Congress of Cardiology
Statistically significant reduction in the risk for the primary outcome on Day 27 Findings generally consistent across the left ventricular...
Cytokinetics Presents Positive Results From Cohort 4 of REDWOOD-HCM and Long-Term Results From FOREST-HCM at the American College of Cardiology 72nd Annual Scientific Session
Treatment with Aficamten Resulted in Significant Improvements in Heart Failure Symptoms and Cardiac Biomarkers in Patients with Non-Obstructive HCM, Supporting Advancement...
Lexicon Reveals “INTO THE DARK” Awareness Campaign About Vulnerable and Dangerous Period of Time Faced by Heart Failure Patients Following Hospitalization
Into the Dark Into the Dark Campaign ImageEmphasizes challenges faced by patients and clinicians within the first 30 days after...
Kane Biotech Clarifies Terms of Credit Facility
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, March 03, 2023 (GLOBE...
MDxHealth Shareholder Transparency Declarations
NEWS RELEASE – REGULATED INFORMATIONMARCH 3, 2023, 4:30 pm ET/ 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – March 3,...
22nd Century Group (XXII) Secures $21 Million Debt Financing to Expand Working Capital for Growth Initiatives
Supports Accelerated Expansion of VLN Multi-State Retail Channels, GVB Global Ingredients and CDMO BusinessBUFFALO, N.Y., March 03, 2023 (GLOBE NEWSWIRE)...
Ractigen Therapeutics Receives FDA Orphan Drug Designation for the novel oligonucleotide conjugate RAG-17 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
JIANGSU, China, March 03, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics announced today that the U.S. Food and Drug Administration (FDA)...
Stereotaxis Reports 2022 Full Year Financial Results
ST. LOUIS, March 03, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for...
LumiraDx to Present at Raymond James Institutional Investors Conference
LONDON, March 03, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX) (the “Company”) today announced that Chief Financial Officer, Dorian...
Smile Health Orthodontics (SHOsmile) Adds New Los Angeles Practice Location And New Patient Rewards Program
The new practice is at 1462 S. Robertson Boulevard in Los Angeles, CA, and next to pediatric dentist Dr. David...
Radiopharm Theranostics Partners With Next Generation Preclinical Platform for Therapeutic Radiopharmaceuticals
SYDNEY, Australia, March 03, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of radiopharmaceutical products...
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the American Academy of Neurology 75th Annual Meeting
NEW YORK, March 03, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data...
Alpha Tau Announces Grant of Expanded Radioactive License and Final Pre-Clinical Laboratory Regulatory Approval at its Jerusalem Headquarters
JERUSALEM, March 03, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the...
Surgalign to Participate at the 2023 AAOS Annual Meeting OrthoDome in Las Vegas
Dr. Rick C. Sasso, renowned spinal surgeon to highlight Surgalign’s HOLO Portal™ Surgical Guidance System on the OrthoDome Panel on...
Assure Announces Reverse Stock Split
DENVER, March 03, 2023 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative...